{"url_path":"/sec/bglc/8-k/2026-06-05/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1737523/0001477932-26-003658-index.html","accession_number":"0001477932-26-003658","cik":"0001737523","ticker":"BGLC","issuer_name":"BioNexus Gene Lab Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1737523/0001477932-26-003658-index.html","primary_entity_key":"0001737523","primary_entity_name":"BioNexus Gene Lab Corp"},"word_count":178,"has_tables":true,"body_markdown":"**Item 8.01. Other Events**\n\n** **\n\nOn May 29, 2026, BioNexus Gene Lab Corp. (the “Company”) issued a press release titled “BioNexus Gene Lab Corp. Calls for Malaysia-China Biotechnology Cooperation to Move Beyond Trade into Co-Development,” highlighting the Company’s participation in the 2026 China-Malaysia Economic Cooperation Outlook Forum held on May 21, 2026 in Kuala Lumpur, Malaysia, and the Company’s views regarding Malaysia-China biotechnology cooperation, precision healthcare collaboration, cross-border biotechnology commercialization and related platform-building opportunities.\n\n \n\nA copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\n \n\nThe information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing."}